{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:03Z","timestamp":1786979883849,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,4,27]],"date-time":"2016-04-27T00:00:00Z","timestamp":1461715200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s00259-016-3400-y","type":"journal-article","created":{"date-parts":[[2016,4,26]],"date-time":"2016-04-26T19:28:46Z","timestamp":1461698926000},"page":"1988-1994","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative 124I-NaI-PET\/CT in patients with papillary thyroid cancer"],"prefix":"10.1007","volume":"43","author":[{"given":"Amir","family":"Sabet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Binse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Grafe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Ezziddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"G\u00f6rges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten D.","family":"Poeppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Bockisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra J.","family":"Rosenbaum-Krumme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,27]]},"reference":[{"key":"3400_CR1","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1056\/NEJM199801293380506","volume":"338","author":"MJ Schlumberger","year":"1998","unstructured":"Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297\u2013306. doi: 10.1056\/NEJM199801293380506 .","journal-title":"N Engl J Med"},{"key":"3400_CR2","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0140-6736(03)12488-9","volume":"361","author":"SI Sherman","year":"2003","unstructured":"Sherman SI. Thyroid carcinoma. Lancet. 2003;361:501\u201311.","journal-title":"Lancet"},{"key":"3400_CR3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/107327480000700302","volume":"7","author":"DS Dean","year":"2000","unstructured":"Dean DS, Hay ID. Prognostic indicators in differentiated thyroid carcinoma. Cancer Control. 2000;7:229\u201339.","journal-title":"Cancer Control"},{"key":"3400_CR4","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1200\/JCO.2012.42.4457","volume":"31","author":"L Yang","year":"2013","unstructured":"Yang L, Shen W, Sakamoto N. Population-based study evaluating and predicting the probability of death resulting from thyroid cancer and other causes among patients with thyroid cancer. J Clin Oncol. 2013;31:468\u201374. doi: 10.1200\/JCO.2012.42.4457 .","journal-title":"J Clin Oncol"},{"key":"3400_CR5","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0002-9610(05)80732-9","volume":"164","author":"MC Coburn","year":"1992","unstructured":"Coburn MC, Wanebo HJ. Prognostic factors and management considerations in patients with cervical metastases of thyroid cancer. Am J Surg. 1992;164:671\u20136.","journal-title":"Am J Surg"},{"key":"3400_CR6","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1002\/cncr.21653","volume":"106","author":"CI Lundgren","year":"2006","unstructured":"Lundgren CI, Hall P, Dickman PW, Zedenius J. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case\u2013control study. Cancer. 2006;106:524\u201331. doi: 10.1002\/cncr.21653 .","journal-title":"Cancer"},{"key":"3400_CR7","first-page":"5393","volume":"7","author":"K Guo","year":"2014","unstructured":"Guo K, Wang Z. Risk factors influencing the recurrence of papillary thyroid carcinoma: a systematic review and meta-analysis. Int J Clin Exp Pathol. 2014;7:5393\u2013403.","journal-title":"Int J Clin Exp Pathol"},{"key":"3400_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s00423-013-1057-6","volume":"398","author":"H Dralle","year":"2013","unstructured":"Dralle H, Musholt TJ, Schabram J, Steinmuller T, Frilling A, Simon D, et al. German association of endocrine surgeons practice guideline for the surgical management of malignant thyroid tumors. Langenbecks Arch Surg. 2013;398:347\u201375. doi: 10.1007\/s00423-013-1057-6 .","journal-title":"Langenbecks Arch Surg"},{"key":"3400_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 american thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1\u2013133. doi: 10.1089\/thy.2015.0020 .","journal-title":"Thyroid"},{"key":"3400_CR10","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1089\/thy.2009.0110","volume":"19","author":"DS Cooper","year":"2009","unstructured":"Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167\u2013214. doi: 10.1089\/thy.2009.0110 .","journal-title":"Thyroid"},{"issue":"Suppl 4","key":"3400_CR11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/annonc\/mdp156","volume":"20","author":"F Pacini","year":"2009","unstructured":"Pacini F, Castagna MG, Brilli L, Pentheroudakis G, Group EGW. Differentiated thyroid cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20 Suppl 4:143\u20136. doi: 10.1093\/annonc\/mdp156 .","journal-title":"Ann Oncol"},{"key":"3400_CR12","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nrendo.2013.153","volume":"9","author":"A Bockisch","year":"2013","unstructured":"Bockisch A, Rosenbaum-Krumme S. Cancer: the effect of radioiodine therapy after total thyroidectomy. Nat Rev Endocrinol. 2013;9:511\u20132. doi: 10.1038\/nrendo.2013.153 .","journal-title":"Nat Rev Endocrinol"},{"key":"3400_CR13","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.otc.2010.02.003","volume":"43","author":"A Sabet","year":"2010","unstructured":"Sabet A, Kim M. Postoperative management of differentiated thyroid cancer. Otolaryngol Clin North Am. 2010;43:329\u201351. doi: 10.1016\/j.otc.2010.02.003 . viii-ix.","journal-title":"Otolaryngol Clin North Am"},{"key":"3400_CR14","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1089\/thy.2010.0178","volume":"20","author":"RM Tuttle","year":"2010","unstructured":"Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American thyroid association staging system. Thyroid: Off J Am Thyroid Assoc. 2010;20:1341\u20139. doi: 10.1089\/thy.2010.0178 .","journal-title":"Thyroid: Off J Am Thyroid Assoc"},{"key":"3400_CR15","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1530\/EJE-11-0466","volume":"165","author":"MG Castagna","year":"2011","unstructured":"Castagna MG, Maino F, Cipri C, Belardini V, Theodoropoulou A, Cevenini G, et al. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol. 2011;165:441\u20136. doi: 10.1530\/EJE-11-0466 .","journal-title":"Eur J Endocrinol"},{"key":"3400_CR16","doi-asserted-by":"publisher","first-page":"591285","DOI":"10.1155\/2014\/591285","volume":"2014","author":"A Cano-Palomares","year":"2014","unstructured":"Cano-Palomares A, Castells I, Capel I, Bella MR, Barcons S, Serrano A, et al. Response to initial therapy of differentiated thyroid cancer predicts the long-term outcome better than classical risk stratification systems. Int J Endocrinol. 2014;2014:591285. doi: 10.1155\/2014\/591285 .","journal-title":"Int J Endocrinol"},{"key":"3400_CR17","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s00259-012-2331-5","volume":"40","author":"C Pont de","year":"2013","unstructured":"de Pont C, Halders S, Bucerius J, Mottaghy F, Brans B. 124I PET\/CT in the pretherapeutic staging of differentiated thyroid carcinoma: comparison with posttherapy 131I SPECT\/CT. Eur J Nucl Med Mol Imaging. 2013;40:693\u2013700. doi: 10.1007\/s00259-012-2331-5 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3400_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3413\/Nukmed-0711-14-12","volume":"54","author":"W Jentzen","year":"2015","unstructured":"Jentzen W, Moldovan AS, Ruhlmann M, Gorges R, Bockisch A, Rosenbaum-Krumme S. Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients. Dosimetry-based model for estimation. Nuklearmedizin. 2015;54:137\u201343. doi: 10.3413\/Nukmed-0711-14-12 .","journal-title":"Nuklearmedizin"},{"key":"3400_CR19","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2967\/jnumed.107.047159","volume":"49","author":"W Jentzen","year":"2008","unstructured":"Jentzen W, Freudenberg L, Eising EG, Sonnenschein W, Knust J, Bockisch A. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J Nucl Med. 2008;49:1017\u201323. doi: 10.2967\/jnumed.107.047159 .","journal-title":"J Nucl Med"},{"key":"3400_CR20","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.2967\/jnumed.114.144089","volume":"55","author":"W Jentzen","year":"2014","unstructured":"Jentzen W, Hoppenbrouwers J, van Leeuwen P, van der Velden D, van de Kolk R, Poeppel TD, et al. Assessment of lesion response in the initial radioiodine treatment of differentiated thyroid cancer using 124I PET imaging. J Nucl Med. 2014;55:1759\u201365. doi: 10.2967\/jnumed.114.144089 .","journal-title":"J Nucl Med"},{"key":"3400_CR21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000354537","volume":"2","author":"L Leenhardt","year":"2013","unstructured":"Leenhardt L, Erdogan MF, Hegedus L, Mandel SJ, Paschke R, Rago T, et al. 2013 European thyroid association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer. Eur Thyroid J. 2013;2:147\u201359. doi: 10.1159\/000354537 .","journal-title":"Eur Thyroid J"},{"key":"3400_CR22","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1200\/JCO.2014.59.8391","volume":"33","author":"MA Adam","year":"2015","unstructured":"Adam MA, Pura J, Goffredo P, Dinan MA, Reed SD, Scheri RP, et al. Presence and number of lymph node metastases Are associated with compromised survival for patients younger than Age 45 years with papillary thyroid cancer. J Clin Oncol. 2015;33:2370\u20135. doi: 10.1200\/JCO.2014.59.8391 .","journal-title":"J Clin Oncol"},{"key":"3400_CR23","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1245\/s10434-013-3258-1","volume":"21","author":"IS Ryu","year":"2014","unstructured":"Ryu IS, Song CI, Choi SH, Roh JL, Nam SY, Kim SY. Lymph node ratio of the central compartment is a significant predictor for locoregional recurrence after prophylactic central neck dissection in patients with thyroid papillary carcinoma. Ann Surg Oncol. 2014;21:277\u201383. doi: 10.1245\/s10434-013-3258-1 .","journal-title":"Ann Surg Oncol"},{"key":"3400_CR24","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1530\/EJE-12-0744","volume":"168","author":"MJ Jeon","year":"2013","unstructured":"Jeon MJ, Yoon JH, Han JM, Yim JH, Hong SJ, Song DE, et al. The prognostic value of the metastatic lymph node ratio and maximal metastatic tumor size in pathological N1a papillary thyroid carcinoma. Eur J Endocrinol. 2013;168:219\u201325. doi: 10.1530\/EJE-12-0744 .","journal-title":"Eur J Endocrinol"},{"key":"3400_CR25","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.surg.2013.06.043","volume":"154","author":"S Young","year":"2013","unstructured":"Young S, Harari A, Smooke-Praw S, Ituarte PH, Yeh MW. Effect of reoperation on outcomes in papillary thyroid cancer. Surgery. 2013;154:1354\u201361. doi: 10.1016\/j.surg.2013.06.043 . discussion 61\u20132.","journal-title":"Surgery"},{"key":"3400_CR26","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1002\/lary.23371","volume":"122","author":"RP Tufano","year":"2012","unstructured":"Tufano RP, Bishop J, Wu G. Reoperative central compartment dissection for patients with recurrent\/persistent papillary thyroid cancer: efficacy, safety, and the association of the BRAF mutation. Laryngoscope. 2012;122:1634\u201340. doi: 10.1002\/lary.23371 .","journal-title":"Laryngoscope"},{"key":"3400_CR27","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1210\/jc.2010-0063","volume":"95","author":"O Al-Saif","year":"2010","unstructured":"Al-Saif O, Farrar WB, Bloomston M, Porter K, Ringel MD, Kloos RT. Long-term efficacy of lymph node reoperation for persistent papillary thyroid cancer. J Clin Endocrinol Metab. 2010;95:2187\u201394. doi: 10.1210\/jc.2010-0063 .","journal-title":"J Clin Endocrinol Metab"},{"key":"3400_CR28","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1089\/thy.2006.16.1229","volume":"16","author":"J Jonklaas","year":"2006","unstructured":"Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid: Off J Am Thyroid Assoc. 2006;16:1229\u201342. doi: 10.1089\/thy.2006.16.1229 .","journal-title":"Thyroid: Off J Am Thyroid Assoc"},{"key":"3400_CR29","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1530\/eje.1.02014","volume":"153","author":"F Pacini","year":"2005","unstructured":"Pacini F, Schlumberger M, Harmer C, Berg GG, Cohen O, Duntas L, et al. Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol. 2005;153:651\u20139. doi: 10.1530\/eje.1.02014 .","journal-title":"Eur J Endocrinol"},{"key":"3400_CR30","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/RLU.0b013e31805375ca","volume":"32","author":"MR Pelizzo","year":"2007","unstructured":"Pelizzo MR, Boschin IM, Toniato A, Piotto A, Pagetta C, Gross MD, et al. Papillary thyroid carcinoma: 35-year outcome and prognostic factors in 1858 patients. Clin Nucl Med. 2007;32:440\u20134. doi: 10.1097\/RLU.0b013e31805375ca .","journal-title":"Clin Nucl Med"},{"key":"3400_CR31","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1530\/eje.1.02158","volume":"154","author":"F Pacini","year":"2006","unstructured":"Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787\u2013803. doi: 10.1530\/eje.1.02158 .","journal-title":"Eur J Endocrinol"},{"key":"3400_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1530\/EJE-13-0524","volume":"170","author":"MJ Jeon","year":"2014","unstructured":"Jeon MJ, Kim WG, Park WR, Han JM, Kim TY, Song DE, et al. Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma. Eur J Endocrinol. 2014;170:23\u201330. doi: 10.1530\/EJE-13-0524 .","journal-title":"Eur J Endocrinol"},{"key":"3400_CR33","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1530\/EJE-13-0888","volume":"170","author":"C Lepoutre-Lussey","year":"2014","unstructured":"Lepoutre-Lussey C, Maddah D, Golmard JL, Russ G, Tissier F, Tresallet C, et al. Post-operative neck ultrasound and risk stratification in differentiated thyroid cancer patients with initial lymph node involvement. Eur J Endocrinol. 2014;170:837\u201346. doi: 10.1530\/EJE-13-0888 .","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 1","key":"3400_CR34","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1007\/s00259-011-1773-5","volume":"38","author":"LS Freudenberg","year":"2011","unstructured":"Freudenberg LS, Jentzen W, Stahl A, Bockisch A, Rosenbaum-Krumme SJ. Clinical applications of 124I-PET\/CT in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2011;38 Suppl 1:S48\u201356. doi: 10.1007\/s00259-011-1773-5 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3400_CR35","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1089\/thy.2009.0430","volume":"20","author":"D Nostrand Van","year":"2010","unstructured":"Van Nostrand D, Moreau S, Bandaru VV, Atkins F, Chennupati S, Mete M, et al. (124)I positron emission tomography versus (131)I planar imaging in the identification of residual thyroid tissue and\/or metastasis in patients who have well-differentiated thyroid cancer. Thyroid. 2010;20:879\u201383. doi: 10.1089\/thy.2009.0430 .","journal-title":"Thyroid"},{"key":"3400_CR36","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1007\/s00259-007-0660-6","volume":"35","author":"HT Phan","year":"2008","unstructured":"Phan HT, Jager PL, Paans AM, Plukker JT, Sturkenboom MG, Sluiter WJ, et al. The diagnostic value of 124I-PET in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35:958\u201365. doi: 10.1007\/s00259-007-0660-6 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3400_CR37","doi-asserted-by":"publisher","DOI":"10.1177\/0284185115594645","author":"T Haslerud","year":"2015","unstructured":"Haslerud T, Brauckhoff K, Reisaeter L, Kufner-Lein R, Heinecke A, Varhaug JE, et al. F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis. Acta Radiol. 2015. doi: 10.1177\/0284185115594645 .","journal-title":"Acta Radiol"},{"key":"3400_CR38","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1210\/jcem.85.3.6458","volume":"85","author":"W Wang","year":"2000","unstructured":"Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab. 2000;85:1107\u201313. doi: 10.1210\/jcem.85.3.6458 .","journal-title":"J Clin Endocrinol Metab"},{"key":"3400_CR39","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s002590050493","volume":"26","author":"F Grunwald","year":"1999","unstructured":"Grunwald F, Kalicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med. 1999;26:1547\u201352.","journal-title":"Eur J Nucl Med"},{"key":"3400_CR40","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s00259-012-2065-4","volume":"39","author":"SJ Rosenbaum-Krumme","year":"2012","unstructured":"Rosenbaum-Krumme SJ, Gorges R, Bockisch A, Binse I. (1)(8)F-FDG PET\/CT changes therapy management in high-risk DTC after first radioiodine therapy. Eur J Nucl Med Mol Imaging. 2012;39:1373\u201380. doi: 10.1007\/s00259-012-2065-4 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3400_CR41","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1097\/RLU.0b013e318125037a","volume":"32","author":"A Iagaru","year":"2007","unstructured":"Iagaru A, Kalinyak JE, McDougall IR. F-18 FDG PET\/CT in the management of thyroid cancer. Clin Nucl Med. 2007;32:690\u20135. doi: 10.1097\/RLU.0b013e318125037a .","journal-title":"Clin Nucl Med"},{"key":"3400_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/hed.23881","author":"R Caetano","year":"2014","unstructured":"Caetano R, Bastos CR, de Oliveira IA, da Silva RM, Fortes CP, Pepe VL, et al. Accuracy of positron emission tomography and positron emission tomography-CT in the detection of differentiated thyroid cancer recurrence with negative I whole-body scan results: a meta-analysis. Head Neck. 2014. doi: 10.1002\/hed.23881 .","journal-title":"Head Neck"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-016-3400-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-016-3400-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-016-3400-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T21:53:00Z","timestamp":1567806780000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-016-3400-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,27]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["3400"],"URL":"https:\/\/doi.org\/10.1007\/s00259-016-3400-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,27]]}}}